While the group's medical arm was the "key" growth driver, the broker said that the nuclear and security screening businesses would provide "immediately realisable" earnings
() will achieve cash breakeven this year, according to analysts at , who on Friday reiterated their ‘buy’ rating and 45p target price on the stock.
The broker said they expected revenue growth for the radiation detection specialist to continue in the “mid- to high-teens range”, adding that the group’s medical imaging arm was the “key medium-term driver” of growth.
Cantor also said that the company’s nuclear and security screening offerings would provide “more immediately realisable earnings and cash”.
Overall, the broker said Kromek was building “a strong customer, manufacturing and intellectual property base”, with cash breakeven the next milestone for the group.
In mid-afternoon trading, Kromek shares were 1% lower at 24.3p.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Kromek Group PLC named herein, including the promotion by the Company of Kromek Group PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE